ORCHIECTOMY AND ORCHIECTOMY PLUS MITOMYCIN C FOR METASTATIC PROSTATE CANCER IN PATIENTS WITH POOR PROGNOSIS: THE FINAL RESULTS OF A EUROPEAN ORGANIZATION FOR RESEARCH IN CANCER THERAPY GENITOURINARY GROUP TRIAL

医学 睾丸切除术 泌尿生殖系统 前列腺癌 泌尿科 肿瘤科 丝裂霉素C 前列腺 癌症 外科 内科学
作者
Theo M. de Reijke,Frans I. Keuppens,Peter Whelan,Jan Kliment,M. R. G. Robinson,Lesley-Ann Rea,Richard J Sylvester
出处
期刊:The Journal of Urology [Lippincott Williams & Wilkins]
卷期号:162 (5): 1658-1658 被引量:24
标识
DOI:10.1016/s0022-5347(05)68191-8
摘要

PURPOSE: The outcome of patients with symptomatic metastatic prostate cancer is poor and improved treatment regimens are urgently needed. Theoretically, the combination of orchiectomy and chemotherapy could reduce androgen sensitive and insensitive cells in the prostate. This European Organization for Research in Cancer Therapy Genitourinary Group randomized, multicenter phase III trial demonstrates the outcome of orchiectomy alone versus orchiectomy followed by intravenous mitomycin C. MATERIALS AND METHODS: A total of 189 patients with metastatic prostate cancer and poor prognostic factors were randomized in this trial by 42 institutions. Of these patients 184 (97%) were eligible for study, including 90 treated with orchiectomy alone (orchiectomy only arm) and 94 treated with orchiectomy followed by 15 mg./m.2 mitomycin C in 1 week (combined treatment arm). Mitomycin C was administered every 6 weeks and treatment was continued as long as tolerance and patient compliance allowed, and no progression was observed. Objective and subjective criteria for progression were clearly defined in the protocol. RESULTS: Patient and tumor characteristics were well balanced between the 2 treatment arms. At a median followup of 4.2 years 144 patients had died, including 112 of prostate cancer. No significant differences for time to overall (p = 0.17), subjective (p = 0.25) and objective (p = 0.08) progression were found between the 2 treatment groups. For progression-free survival no difference was noted (p = 0.67) between the 2 treatment groups but a trend in favor of orchiectomy alone was observed for overall survival (p = 0.04). Mitomycin C induced considerable hematological, gastrointestinal, renal and pulmonary toxicity leading to discontinuation in 31% of patients with pulmonary toxicity and 7% with renal deterioration. In addition, the quality of life evaluation revealed significant reduction in the combined treatment arm. CONCLUSIONS: Based on the results of this randomized phase III study orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognostic factors cannot be recommended due to failure of improvement in survival and reduced quality of life parameters.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研蚂蚁发布了新的文献求助10
刚刚
AA发布了新的文献求助10
1秒前
itsuka完成签到,获得积分10
2秒前
浮云发布了新的文献求助10
3秒前
Elsevier大王的应助被twive采纳,获得30
5秒前
xiaobin完成签到 ,获得积分10
5秒前
ahhh完成签到,获得积分10
5秒前
5秒前
jht456完成签到,获得积分10
6秒前
虚心向上完成签到 ,获得积分10
6秒前
华仔的应助被KIKI采纳,获得10
6秒前
橙花完成签到,获得积分10
6秒前
7秒前
7秒前
9秒前
周末完成签到,获得积分10
9秒前
10秒前
orixero的应助被科研通管家采纳,获得10
11秒前
Jasper的应助被科研通管家采纳,获得10
11秒前
daomaihu发布了新的文献求助100
11秒前
乐空思的应助被科研通管家采纳,获得30
11秒前
无极微光的应助被科研通管家采纳,获得20
11秒前
汉堡包的应助被科研通管家采纳,获得10
11秒前
11秒前
科目三的应助被科研通管家采纳,获得10
11秒前
12秒前
脑洞疼的应助被科研通管家采纳,获得10
12秒前
深情安青的应助被科研通管家采纳,获得10
12秒前
科研小白给科研小白的求助进行了留言
12秒前
李爱国的应助被科研通管家采纳,获得10
12秒前
12秒前
zq123完成签到,获得积分10
12秒前
12秒前
斯文败类的应助被科研蚂蚁采纳,获得10
12秒前
wanci的应助被科研通管家采纳,获得10
12秒前
12秒前
哈哈哈发布了新的文献求助10
13秒前
花随幽人落完成签到,获得积分10
13秒前
扎克斯完成签到,获得积分10
13秒前
科研通AI6.2的应助被Lila采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175267
求助须知:如何正确求助?哪些是违规求助? 9567035
关于积分的说明 21789830
捐赠科研通 7769741
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556149
邀请新用户注册赠送积分活动 2477241